nodes	percent_of_prediction	percent_of_DWPC	metapath
Brompheniramine—Captodiame—DRD3—Gilles de la Tourette syndrome	0.027	0.488	CrCbGaD
Brompheniramine—CHRM4—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0168	0.023	CbGpPWpGaD
Brompheniramine—CHRM5—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0161	0.022	CbGpPWpGaD
Brompheniramine—CHRM4—nervous system—Gilles de la Tourette syndrome	0.015	0.07	CbGeAlD
Brompheniramine—CHRM4—central nervous system—Gilles de la Tourette syndrome	0.0144	0.0674	CbGeAlD
Brompheniramine—CHRM4—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0143	0.0196	CbGpPWpGaD
Brompheniramine—CHRM4—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0139	0.019	CbGpPWpGaD
Brompheniramine—CHRM5—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0137	0.0187	CbGpPWpGaD
Brompheniramine—CHRM5—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0133	0.0182	CbGpPWpGaD
Brompheniramine—CHRM4—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0129	0.0177	CbGpPWpGaD
Brompheniramine—CHRM5—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0124	0.017	CbGpPWpGaD
Brompheniramine—CHRM4—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.012	0.0165	CbGpPWpGaD
Brompheniramine—CHRM5—nervous system—Gilles de la Tourette syndrome	0.0117	0.0547	CbGeAlD
Brompheniramine—CHRM4—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0117	0.016	CbGpPWpGaD
Brompheniramine—CHRM5—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0115	0.0158	CbGpPWpGaD
Brompheniramine—CHRM4—brain—Gilles de la Tourette syndrome	0.0115	0.0535	CbGeAlD
Brompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0113	0.0155	CbGpPWpGaD
Brompheniramine—Chlorphenamine—SLC6A3—Gilles de la Tourette syndrome	0.0113	0.205	CrCbGaD
Brompheniramine—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0113	0.0155	CbGpPWpGaD
Brompheniramine—CHRM5—central nervous system—Gilles de la Tourette syndrome	0.0113	0.0527	CbGeAlD
Brompheniramine—CHRM3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0113	0.0154	CbGpPWpGaD
Brompheniramine—CHRM5—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0112	0.0153	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0112	0.0153	CbGpPWpGaD
Brompheniramine—CHRM4—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0109	0.0149	CbGpPWpGaD
Brompheniramine—CHRM5—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0104	0.0142	CbGpPWpGaD
Brompheniramine—HRH1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00967	0.0132	CbGpPWpGaD
Brompheniramine—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00964	0.0132	CbGpPWpGaD
Brompheniramine—CHRM3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00961	0.0132	CbGpPWpGaD
Brompheniramine—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00952	0.013	CbGpPWpGaD
Brompheniramine—HRH1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00939	0.0129	CbGpPWpGaD
Brompheniramine—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00936	0.0128	CbGpPWpGaD
Brompheniramine—CHRM3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00933	0.0128	CbGpPWpGaD
Brompheniramine—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00924	0.0126	CbGpPWpGaD
Brompheniramine—CHRM4—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00906	0.0124	CbGpPWpGaD
Brompheniramine—CHRM5—brain—Gilles de la Tourette syndrome	0.00896	0.0418	CbGeAlD
Brompheniramine—HRH1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00875	0.012	CbGpPWpGaD
Brompheniramine—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00872	0.0119	CbGpPWpGaD
Brompheniramine—CHRM3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00869	0.0119	CbGpPWpGaD
Brompheniramine—CHRM5—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00867	0.0119	CbGpPWpGaD
Brompheniramine—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00861	0.0118	CbGpPWpGaD
Brompheniramine—Promazine—DRD4—Gilles de la Tourette syndrome	0.00826	0.149	CrCbGaD
Brompheniramine—HRH1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00813	0.0111	CbGpPWpGaD
Brompheniramine—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0081	0.0111	CbGpPWpGaD
Brompheniramine—CHRM3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00808	0.0111	CbGpPWpGaD
Brompheniramine—CHRM2—nervous system—Gilles de la Tourette syndrome	0.00805	0.0376	CbGeAlD
Brompheniramine—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.008	0.011	CbGpPWpGaD
Brompheniramine—HRH1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00789	0.0108	CbGpPWpGaD
Brompheniramine—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00787	0.0108	CbGpPWpGaD
Brompheniramine—CHRM3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00784	0.0107	CbGpPWpGaD
Brompheniramine—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00777	0.0106	CbGpPWpGaD
Brompheniramine—CHRM2—central nervous system—Gilles de la Tourette syndrome	0.00775	0.0362	CbGeAlD
Brompheniramine—CHRM4—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00761	0.0104	CbGpPWpGaD
Brompheniramine—HRH1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00735	0.0101	CbGpPWpGaD
Brompheniramine—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00733	0.01	CbGpPWpGaD
Brompheniramine—CHRM1—nervous system—Gilles de la Tourette syndrome	0.00732	0.0342	CbGeAlD
Brompheniramine—CHRM3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00731	0.01	CbGpPWpGaD
Brompheniramine—CHRM5—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00729	0.00998	CbGpPWpGaD
Brompheniramine—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00723	0.0099	CbGpPWpGaD
Brompheniramine—KCNH2—midbrain—Gilles de la Tourette syndrome	0.00707	0.033	CbGeAlD
Brompheniramine—CHRM1—central nervous system—Gilles de la Tourette syndrome	0.00705	0.0329	CbGeAlD
Brompheniramine—CHRM3—nervous system—Gilles de la Tourette syndrome	0.00655	0.0306	CbGeAlD
Brompheniramine—CHRM3—central nervous system—Gilles de la Tourette syndrome	0.00631	0.0295	CbGeAlD
Brompheniramine—CHRM2—brain—Gilles de la Tourette syndrome	0.00615	0.0287	CbGeAlD
Brompheniramine—HRH1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00613	0.00839	CbGpPWpGaD
Brompheniramine—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00611	0.00836	CbGpPWpGaD
Brompheniramine—CHRM3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00609	0.00833	CbGpPWpGaD
Brompheniramine—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00603	0.00825	CbGpPWpGaD
Brompheniramine—KCNH2—nervous system—Gilles de la Tourette syndrome	0.00581	0.0271	CbGeAlD
Brompheniramine—CHRM1—brain—Gilles de la Tourette syndrome	0.0056	0.0261	CbGeAlD
Brompheniramine—KCNH2—central nervous system—Gilles de la Tourette syndrome	0.0056	0.0261	CbGeAlD
Brompheniramine—HRH1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00515	0.00705	CbGpPWpGaD
Brompheniramine—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00513	0.00703	CbGpPWpGaD
Brompheniramine—CHRM3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00512	0.007	CbGpPWpGaD
Brompheniramine—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00507	0.00694	CbGpPWpGaD
Brompheniramine—CHRM3—brain—Gilles de la Tourette syndrome	0.00501	0.0234	CbGeAlD
Brompheniramine—Promazine—DRD2—Gilles de la Tourette syndrome	0.00493	0.0891	CrCbGaD
Brompheniramine—CYP2B6—nervous system—Gilles de la Tourette syndrome	0.00477	0.0223	CbGeAlD
Brompheniramine—HRH1—nervous system—Gilles de la Tourette syndrome	0.00466	0.0217	CbGeAlD
Brompheniramine—CYP2B6—central nervous system—Gilles de la Tourette syndrome	0.00459	0.0214	CbGeAlD
Brompheniramine—HRH1—central nervous system—Gilles de la Tourette syndrome	0.00448	0.0209	CbGeAlD
Brompheniramine—CYP2E1—nervous system—Gilles de la Tourette syndrome	0.00448	0.0209	CbGeAlD
Brompheniramine—KCNH2—brain—Gilles de la Tourette syndrome	0.00444	0.0207	CbGeAlD
Brompheniramine—CYP2E1—central nervous system—Gilles de la Tourette syndrome	0.00431	0.0201	CbGeAlD
Brompheniramine—CHRM3—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00427	0.00584	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00423	0.00579	CbGpPWpGaD
Brompheniramine—CHRM3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00414	0.00567	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0041	0.00562	CbGpPWpGaD
Brompheniramine—CYP2C8—brain—Gilles de la Tourette syndrome	0.00406	0.019	CbGeAlD
Brompheniramine—Promazine—HTR2A—Gilles de la Tourette syndrome	0.00381	0.0689	CrCbGaD
Brompheniramine—CYP2B6—brain—Gilles de la Tourette syndrome	0.00365	0.017	CbGeAlD
Brompheniramine—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.0036	0.0168	CbGeAlD
Brompheniramine—HRH1—brain—Gilles de la Tourette syndrome	0.00356	0.0166	CbGeAlD
Brompheniramine—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.00354	0.0165	CbGeAlD
Brompheniramine—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00347	0.0162	CbGeAlD
Brompheniramine—CYP2E1—brain—Gilles de la Tourette syndrome	0.00342	0.016	CbGeAlD
Brompheniramine—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.00341	0.0159	CbGeAlD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00327	0.00448	CbGpPWpGaD
Brompheniramine—KCNH2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00298	0.00408	CbGpPWpGaD
Brompheniramine—CHRM4—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00297	0.00407	CbGpPWpGaD
Brompheniramine—CHRM4—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00289	0.00395	CbGpPWpGaD
Brompheniramine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00276	0.00378	CbGpPWpGaD
Brompheniramine—CYP2D6—brain—Gilles de la Tourette syndrome	0.00271	0.0126	CbGeAlD
Brompheniramine—CHRM3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.0027	0.0037	CbGpPWpGaD
Brompheniramine—CHRM4—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00269	0.00368	CbGpPWpGaD
Brompheniramine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00268	0.00367	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00268	0.00367	CbGpPWpGaD
Brompheniramine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00264	0.00362	CbGpPWpGaD
Brompheniramine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00257	0.00351	CbGpPWpGaD
Brompheniramine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0025	0.00342	CbGpPWpGaD
Brompheniramine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00239	0.00327	CbGpPWpGaD
Brompheniramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00236	0.00324	CbGpPWpGaD
Brompheniramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00229	0.00314	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00227	0.00311	CbGpPWpGaD
Brompheniramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00226	0.0031	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00221	0.00302	CbGpPWpGaD
Brompheniramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0022	0.00301	CbGpPWpGaD
Brompheniramine—CHRM5—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00217	0.00296	CbGpPWpGaD
Brompheniramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00214	0.00293	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00205	0.00281	CbGpPWpGaD
Brompheniramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00205	0.0028	CbGpPWpGaD
Brompheniramine—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00198	0.00271	CbGpPWpGaD
Brompheniramine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00194	0.00265	CbGpPWpGaD
Brompheniramine—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00192	0.00263	CbGpPWpGaD
Brompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00187	0.00256	CbGpPWpGaD
Brompheniramine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00186	0.00255	CbGpPWpGaD
Brompheniramine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00185	0.00254	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00184	0.00251	CbGpPWpGaD
Brompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00181	0.00248	CbGpPWpGaD
Brompheniramine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00181	0.00247	CbGpPWpGaD
Brompheniramine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0018	0.00246	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.0018	0.00246	CbGpPWpGaD
Brompheniramine—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00179	0.00245	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00178	0.00244	CbGpPWpGaD
Brompheniramine—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00175	0.00239	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00175	0.00239	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00174	0.00238	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00172	0.00236	CbGpPWpGaD
Brompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00169	0.00231	CbGpPWpGaD
Brompheniramine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00168	0.0023	CbGpPWpGaD
Brompheniramine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00168	0.0023	CbGpPWpGaD
Brompheniramine—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00167	0.00229	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00167	0.00229	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00166	0.00227	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00163	0.00223	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.0016	0.00219	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00159	0.00218	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00159	0.00218	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00157	0.00215	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00156	0.00213	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00155	0.00213	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00155	0.00212	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00154	0.00211	CbGpPWpGaD
Brompheniramine—HRH1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00153	0.00209	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00153	0.00209	CbGpPWpGaD
Brompheniramine—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00152	0.00209	CbGpPWpGaD
Brompheniramine—CHRM3—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00152	0.00208	CbGpPWpGaD
Brompheniramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.0015	0.00205	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00145	0.00198	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00144	0.00197	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00144	0.00197	CbGpPWpGaD
Brompheniramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00143	0.00196	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00142	0.00195	CbGpPWpGaD
Brompheniramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00137	0.00187	CbGpPWpGaD
Brompheniramine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00136	0.00187	CbGpPWpGaD
Brompheniramine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00136	0.00186	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00122	0.00167	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00121	0.00166	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00121	0.00166	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.0012	0.00164	CbGpPWpGaD
Brompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00118	0.00162	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00118	0.00162	CbGpPWpGaD
Brompheniramine—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00118	0.00161	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00118	0.00161	CbGpPWpGaD
Brompheniramine—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00117	0.00161	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00117	0.00161	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00116	0.00159	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00116	0.00159	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00116	0.00159	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00114	0.00156	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0011	0.00151	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0011	0.0015	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00109	0.0015	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00109	0.00149	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00108	0.00148	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00102	0.00139	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00101	0.00139	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00101	0.00138	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00101	0.00138	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—HDC—Gilles de la Tourette syndrome	0.000998	0.00137	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000997	0.00136	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000988	0.00135	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000978	0.00134	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000974	0.00133	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000946	0.00129	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000924	0.00126	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00092	0.00126	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000897	0.00123	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000885	0.00121	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000881	0.00121	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000859	0.00118	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—HDC—Gilles de la Tourette syndrome	0.000845	0.00116	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000835	0.00114	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.0008	0.0011	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000771	0.00106	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000769	0.00105	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000766	0.00105	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000759	0.00104	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—HDC—Gilles de la Tourette syndrome	0.000754	0.00103	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.000694	0.00095	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000688	0.000942	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—HDC—Gilles de la Tourette syndrome	0.000688	0.000941	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000686	0.000939	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000684	0.000936	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000677	0.000927	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000668	0.000915	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000666	0.000912	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000664	0.000909	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000657	0.0009	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000644	0.000882	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000625	0.000856	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000623	0.000853	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000622	0.000852	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000621	0.00085	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00062	0.000849	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000618	0.000847	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000617	0.000845	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000615	0.000842	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000612	0.000838	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000607	0.000831	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000605	0.000828	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000603	0.000825	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000597	0.000817	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000585	0.000801	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000565	0.000774	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000563	0.000771	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000562	0.000769	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00056	0.000767	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000556	0.000761	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000546	0.000747	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00053	0.000725	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000523	0.000715	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000507	0.000695	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000494	0.000676	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000473	0.000647	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	0.000454	0.000621	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000436	0.000597	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000434	0.000595	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000433	0.000593	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000429	0.000587	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000396	0.000542	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000395	0.00054	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000393	0.000538	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000389	0.000533	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000369	0.000505	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000368	0.000504	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000367	0.000502	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000363	0.000497	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000358	0.000491	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000357	0.000489	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000356	0.000488	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000353	0.000483	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000346	0.000473	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000334	0.000457	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000333	0.000456	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000332	0.000454	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000331	0.000453	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000328	0.00045	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000234	0.00032	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000233	0.000319	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000232	0.000318	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00023	0.000315	CbGpPWpGaD
